Longterm efficiency and safety of intravitreal injections with bevacizumab in patients with neovascularisation or macular edema.
Phase of Trial: Phase IV
Latest Information Update: 04 Jul 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Choroidal neovascularisation; Retinal oedema
- Focus Therapeutic Use
- 29 Apr 2018 Planned number of patients changed from 350 to 500.
- 16 Sep 2014 New trial record